video: Jorn Drappa, senior author of the new study, responding to the question, "What promise does targeting CD40L potentially offer over therapies that target TNFa and IL-17, which are currently under clinical development?". This material relates to a paper that appeared in the Apr. 24, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by J.L. Karnell at Viela Bio in Gaithersburg, MD; and colleagues was titled, "A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity." view more
Credit: Jorn Drappa